These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

713 related items for PubMed ID: 22728934

  • 1. FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality.
    Shalhoub V, Shatzen EM, Ward SC, Davis J, Stevens J, Bi V, Renshaw L, Hawkins N, Wang W, Chen C, Tsai MM, Cattley RC, Wronski TJ, Xia X, Li X, Henley C, Eschenberg M, Richards WG.
    J Clin Invest; 2012 Jul; 122(7):2543-53. PubMed ID: 22728934
    [Abstract] [Full Text] [Related]

  • 2. Effects of unfractionated heparin on renal osteodystrophy and vascular calcification in chronic kidney disease rats.
    Meng Y, Zhang H, Li Y, Li Q, Zuo L.
    Bone; 2014 Jan; 58():168-76. PubMed ID: 24145307
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Parathyroid function in chronic kidney disease: role of FGF23-Klotho axis.
    Koizumi M, Komaba H, Fukagawa M.
    Contrib Nephrol; 2013 Jan; 180():110-23. PubMed ID: 23652554
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Chronic kidney disease: mineral and bone disorder in children.
    Wesseling-Perry K, Salusky IB.
    Semin Nephrol; 2013 Mar; 33(2):169-79. PubMed ID: 23465503
    [Abstract] [Full Text] [Related]

  • 11. Longitudinal evaluation of FGF23 changes and mineral metabolism abnormalities in a mouse model of chronic kidney disease.
    Stubbs JR, He N, Idiculla A, Gillihan R, Liu S, David V, Hong Y, Quarles LD.
    J Bone Miner Res; 2012 Jan; 27(1):38-46. PubMed ID: 22031097
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. FGF23 and the PTH response to paricalcitol in chronic kidney disease.
    D'Arrigo G, Pizzini P, Cutrupi S, Tripepi R, Tripepi G, Mallamaci F, Zoccali C.
    Eur J Clin Invest; 2020 Feb; 50(2):e13196. PubMed ID: 31863599
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Mutant FGF23 prevents the progression of chronic kidney disease but aggravates renal osteodystrophy in uremic rats.
    Kusano K, Saito H, Segawa H, Fukushima N, Miyamoto K.
    J Nutr Sci Vitaminol (Tokyo); 2009 Apr; 55(2):99-105. PubMed ID: 19436134
    [Abstract] [Full Text] [Related]

  • 17. FGF23 neutralization improves bone quality and osseointegration of titanium implants in chronic kidney disease mice.
    Sun N, Guo Y, Liu W, Densmore M, Shalhoub V, Erben RG, Ye L, Lanske B, Yuan Q.
    Sci Rep; 2015 Feb 10; 5():8304. PubMed ID: 25665715
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Chronic Kidney Disease-Mineral Bone Disorder in Korean Patients: a Report from the KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD).
    Kim CS, Bae EH, Ma SK, Han SH, Lee KB, Lee J, Oh KH, Chae DW, Kim SW, KNOW-CKD Study Group.
    J Korean Med Sci; 2017 Feb 10; 32(2):240-248. PubMed ID: 28049234
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.